Original Article

Women's Free-text Comments on their Quality of Life: An Exploratory Analysis from the UK Standardisation of Breast Radiotherapy (START) Trials for Early Breast Cancer

J. Mills*, J.S. Haviland*, C. Moynihan†, J.M. Bliss*, P. Hopwood* on behalf of the START Trial Management Group

*ICR-Clinical Trials and Statistics Unit (ICR-CTSU), Division of Clinical Studies, The Institute of Cancer Research, London UK
†Department of Genetics & Oncology, The Institute of Cancer Research, London UK

Received 20 October 2017; received in revised form 12 February 2018; accepted 6 March 2018

Abstract

Aims: Exploratory analysis of patients’ unsolicited written comments in the first 2 years of the Standardisation of Breast Radiotherapy (START) trial quality of life study highlighted a potential effect of non-treatment-related problems on the ratings and interpretation of patient self-reported questionnaires. At 5 years of follow-up all eligible subjects were invited to write comments to further explore these findings.

Materials and methods: Using inductive qualitative methods informed by the exploratory analysis, comments were allocated to relevant themes. Key patient-reported outcome measures (PROMs), clinical and demographic factors were collated for patients who did and did not comment at 5 years and comparisons between the groups explored.

Results: Of 2208 women completing baseline PROMs, 482 proffered comments from 0 to 24 months, forming nine distinct themes, including chronic conditions, life events and psychosocial concerns. At 5 years, 1041/1727 (60.3%) women contributed comments, of whom 500 randomly selected participants formed the sample for analysis. Findings revealed comorbidity, impaired physical functioning and psychosocial problems as key themes, with prevalent adverse effects from local and systemic treatments. Eight new themes emerged at 5 years, including ageing, concerns about future cancer and positive aspects of care. Women commenting were better educated, slightly older and more likely to have had chemotherapy compared with non-commenters. They had significantly worse PROM scores for global health and key quality of life domains relevant to the difficulties they revealed.

Conclusions: Difficult personal circumstances and other health concerns affected many women’s PROM ratings at 5 years of follow-up, in addition to ongoing cancer treatment effects. Greater attention to multiple sources of distress and adversity could facilitate personalised care and aid interpretation of PROMs.

Key words: Breast cancer; clinical trials; contextual factors; patients’ free-text comments; quality of life; radiotherapy

Introduction

The findings of the Standardisation of Breast Radiotherapy (START) trial’s quality of life substudy [1] provided valuable information for patients and clinical teams about beneficial and unfavourable effects of the radiotherapy treatment groups under comparison, as an aid to future decision-making and clinical care provision. START tested a widely used dose regimen (40 Gy in 15 fractions) and two test schedules of hypofractionated radiotherapy (fractions >2.0 Gy) against the international standard of 50 Gy in 25 fractions, in terms of local tumour control and late normal tissue effects. Findings from patients’ ratings strengthened the evidence in support of the clinical findings in favour of hypofractionated regimens [2,3], which influenced clinical breast radiotherapy practice [4]. The quality of life findings were derived from standardised measures designed within a biomedical framework, which included questions relating...
to protocol-specific radiotherapy effects that helped distinguish between the regimens.

Such measures are very effective in supporting key end points in clinical trials and cover a range of largely biomedical domains to facilitate multidimensional comparisons between treatment arms and have contributed to clinical improvement. However, they are not designed to encompass non-trial circumstances or individual experiences and so may not inform individual care. There has been extensive psychosocial research detailing the multiple and complex effects of breast cancer and its treatment [5–14], but to date there has been little opportunity for patients to express the meaning or relevance of non-breast cancer symptoms, psycho-social problems or functional limitations in the context of a clinical trial [5,15]. However, it is expected that randomisation will eliminate any bias due to individual circumstances for treatment comparisons in the trial setting.

Unexpectedly, during the first 2 years of quality of life data collection in the START trials, 22% of women wrote unsolicited comments at least once, or enclosed letters, when returning their quality of life booklets. These women frequently wanted to ‘explain’ that their responses to specific questionnaire items or subscales reflected the effects of other personal problems, life events or health issues rather than breast cancer or its treatment. Some women thought there should be space for such reporting: ‘Completing the questionnaire I thought there should be a question about whether there are any factors/worries in your daily life that affect your answers’. These patients also expressed concern that if contextual factors were insufficient to influence their questionnaire ratings they could be misattributed to effects of cancer treatments. The potential value of these comments in raising awareness of contextual problems in the clinical setting and of their possible influence on quality of life ratings warranted further exploration. We therefore conducted a qualitative study of the comments proffered up to 2 years and a summary of the sample composition, analysis and findings is presented as supplementary data in Appendix A. These were found to endorse the importance to quality of life of comorbidity and other contextual factors, not captured by the quality of life measures, and the potential for misattribution of ratings to breast cancer outcomes. If generalised, these contextual factors could lead to inferior quality of life outcomes for long-term survivors in whom the interplay of contextual factors, life stress and ageing may impede adjustment and be detrimental to coping, decision-making and ongoing self-management [16–19].

Following on from this, and given the relatively small sample of women who proffered comments early on in the trial, it was decided to invite comments from all women in the START trials completing patient-reported outcome measures (PROMS) at the 5 year assessment. The aims were: (i) to retrospectively explore reported health concerns and adverse contextual factors and see if they endorsed the proffered comments, and (ii) to examine possible associations between quality of life scores derived from the quantitative questionnaire items and patients’ reported health concerns and other adverse contextual factors.

Materials and Methods

Full details of the UK START trials and quality of life substudy have been published separately [1–3]. The START trials were registered as an International Standard Randomised Controlled Trial, number ISRCTN59368779. Patients were recruited to the quality of life study from 31 of 35 radiotherapy centres in the UK between 1998 and 2002 and the main quality of life outcomes were published in 2010 [1]. Ethical approval was obtained from the South Thames Multi-Research Ethics Committee to request additional written comments from all patients completing the 5 year quality of life follow-up assessment; local ethics committee of all participating centres also gave approval. A blank page in the PROMS booklet was included and a patient information letter invited participants to report any health problems or events that they thought might influence the answers they gave in their PROMS booklet (see Appendix B for full text).

The quality of life booklets comprised the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 core questionnaire [20], EORTC QLQ-BR-23 breast cancer-specific module [21], Hospital Anxiety and Depression Scale [22], Body Image Scale [23] and a health economics evaluation [24] for completion at home. The trials office at the Institute of Cancer Research (ICR) first checked the individual’s current health status with their hospital team or family doctor before sending questionnaires. Prompts were sent for non-return of questionnaires by letter or telephone 3 weeks after mailing. At 5 years, all pages with comments in the quality of life booklets were logged on the quality of life study database.

The number of comments received on the 5 year questionnaires was too large to analyse using the entire written records and so comments from a random sample of 500 patients were used for the analysis, which followed a constant comparative methodology [25], as described for the proffered comments (Appendix A). Thus, for each patient commenting, each written comment was allocated to an appropriate theme: initially all nine themes created from the proffered comments analyses were used (Appendix A). Additional themes were formed and labelled, for comments that had not previously been submitted. All decisions ascribing comments to ‘new’ themes were made jointly by at least three coders. Where there was difficulty allocating a theme, a consensus decision was made.

Statistical Methods

Descriptive analyses compared demographic and clinical characteristics, and key quality of life scores between women who did and did not provide comments at 5 years. Quality of life subscale scores at 5 years were calculated as specified in the EORTC scoring manual [26].

A secondary analysis compared quality of life scores in three key domains (global health/quality of life, physical and emotional functioning) and two symptom items (BR23 ‘hot flushes’ and ‘worry about future health’) for women
commenting on an associated theme with women who commented on different themes, to investigate associations between themes and corresponding quality of life scores. EORTC subscales were selected that were considered most likely to reflect differences between patients commenting or not commenting on key areas of concern, based on exploration of data from the proffered comments. For graphical presentation, the EORTC subscales were arbitrarily grouped into the following categories 0–40, 41–60, 61–80, 81–100, as the distributions of scores were highly skewed.

Differences were tested using either the t-test or Mann–Whitney test for continuous variables or the $\chi^2$ test or $\chi^2$ test for trend for categorical variables, as appropriate.

## Results

At 5 years, 91.2% (1728/1893) of eligible women completed quality of life questionnaire booklets and 60.2% (1041/1728) provided written comments; of these, 275/1041 (26.4%) had also proffered comments between 0 and 24 months. Four patients in the random sample selected for this analysis were excluded as their comments indicated only administrative issues. There were no clear differences between the randomised schedules in the proportion of women providing comments at 5 years. A comparison of the characteristics of women commenting or not commenting on key areas of concern, based on exploratory analysis of data from the proffered comments. For emotional functioning and global health quality of life scores were significantly worse for women who commented in the ‘chronic medical and physical functioning’ theme compared with women who had commented in different themes (Figure 2a, b). Similar quality of life differences for emotional functioning and global health quality of life were found for women commenting versus those not commenting in the ‘psychological problems’ theme (Figure 2c, d). Furthermore, significantly more women (34%) commenting on systemic treatment side-effects rated their ‘hot flushes’ in the BR23 subscale as ‘quite a bit’ or ‘very much’ compared with 24.8% of ‘non-commenters’ on this item ($P = 0.018$). Scores on the BR23 ‘future perspective’ item were significantly worse for those commenting on their personal fear of recurrence (45.3% responded ‘quite a bit’ or ‘very much’) compared with women who did not comment on this item (31.6% responded ‘quite a bit’ or very much’; $P = 0.016$).

## Discussion

Women’s free-text comments in the START trials revealed many adverse personal circumstances at 5 years of follow-up as well as current and chronic health and psychosocial difficulties. For some women, breast cancer was not the only or necessarily the main determinant of their quality of life. For others, ongoing or late effects of multimodal breast cancer treatment significantly impaired their wellbeing. Overall, these comments endorsed and extended the proffered comments made by women earlier in the trial. They provide a broad, explanatory dimension to the quality of life ratings and highlight negative effects of comorbidity, life events and adverse psychosocial problems on many individual experiences of cancer and quality of life outcomes. These insights from a national radiotherapy trial setting are novel and informative but also resonate with many issues described by others, using examples from clinical research and practice and patients’ testimonies [6,7]. From these, wide-ranging contextual factors were uncovered that were considered critical to understanding patients’ resources and experience of cancer.

We confirmed a significant negative impact on quality of life ratings for ‘commenters’ compared with ‘non-commenters’ over all functional domains, as well as specificity of the effect of particular themes on related quality of life domains. Comments on psychological problems often referred to specific reasons for their quality of life ratings,
Table 1
Characteristics of women who wrote comments at 5 years and women who did not

|                                | Women who commented at 5 years | Women who returned 5 year form but who did not comment | P-value |
|--------------------------------|--------------------------------|--------------------------------------------------------|---------|
| Age at baseline (years): mean (standard deviation) [range] | 57.4 (10.0) [27–85] | 56.2 (9.8) [28–82] | 0.021* |
| Highest level of education achieved |                                |                                                        | <0.001† |
| None                            | 326/981 (33.2)                | 284/624 (45.5)                                          |         |
| School certificate/O level/GCSE/NVQ or equivalent | 275/981 (28.0) | 185/624 (29.6) |         |
| A level/HND or equivalent       | 60/981 (6.1)                  | 30/624 (4.8)                                           |         |
| Degree, postgraduate or professional qualification | 282/981 (28.7) | 97/624 (15.5) |         |
| Unknown – not completed on form | 38/981 (3.9)                  | 28/624 (4.5)                                           |         |
| Type of surgery                 |                                |                                                        | 0.105‡ |
| Breast-conserving surgery       | 906 (87.0)                    | 578 (84.1)                                              |         |
| Mastectomy                      | 135 (13.0)                    | 109 (15.9)                                              |         |
| Chemotherapy                    |                                |                                                        | 0.025§ |
| No                              | 746 (71.7)                    | 454 (66.1)                                              |         |
| Yes                             | 295 (28.3)                    | 229 (33.3)                                              |         |
| Unknown                         | 0                             | 4 (0.6)                                                 |         |
| Tamoxifen                       |                                |                                                        | 0.138∥ |
| No                              | 161 (15.5)                    | 125 (18.2)                                              |         |
| Yes                             | 880 (84.5)                    | 558 (81.2)                                              |         |
| Unknown                         | 0                             | 4 (0.6)                                                 |         |
| EORTC QLQ-C30 subscale scores at 5 years |                                |                                                        | <0.001‡ |
| Global health/quality of life    |                                |                                                        |         |
| 0–40                            | 76 (7.3)                      | 34 (4.9)                                                |         |
| 41–60                           | 204 (19.6)                    | 102 (14.8)                                              |         |
| 61–80                           | 267 (25.6)                    | 167 (24.3)                                              |         |
| 81–100                          | 489 (47.0)                    | 379 (55.2)                                              |         |
| Unknown                         | 5 (0.5)                       | 5 (0.7)                                                 |         |
| Physical functioning            |                                |                                                        | <0.001‡ |
| 0–40                            | 41 (3.9)                      | 19 (2.8)                                                |         |
| 41–60                           | 105 (10.1)                    | 43 (6.3)                                                |         |
| 61–80                           | 228 (21.9)                    | 115 (16.7)                                              |         |
| 81–100                          | 666 (64.0)                    | 508 (73.9)                                              |         |
| Unknown                         | 1 (0.1)                       | 2 (0.3)                                                 |         |
| Emotional functioning           |                                |                                                        | 0.011‡ |
| 0–40                            | 46 (4.4)                      | 32 (4.7)                                                |         |
| 41–60                           | 129 (12.4)                    | 53 (7.7)                                                |         |
| 61–80                           | 284 (27.3)                    | 172 (25.0)                                              |         |
| 81–100                          | 579 (55.6)                    | 424 (61.7)                                              |         |
| Unknown                         | 3 (0.3)                       | 6 (0.9)                                                 |         |
| Role functioning                |                                |                                                        | <0.001‡ |
| 0–40                            | 103 (9.9)                     | 33 (4.8)                                                |         |
| 41–60                           | 46 (4.4)                      | 18 (2.6)                                                |         |
| 61–80                           | 183 (17.6)                    | 79 (11.5)                                               |         |
| 81–100                          | 705 (67.7)                    | 552 (80.3)                                              |         |
| Unknown                         | 4 (0.4)                       | 5 (0.7)                                                 |         |
| Social functioning              |                                |                                                        | <0.001‡ |
| 0–40                            | 59 (5.7)                      | 22 (3.2)                                                |         |
| 41–60                           | 41 (3.9)                      | 9 (1.3)                                                 |         |
| 61–80                           | 136 (13.1)                    | 63 (9.2)                                                |         |
| 81–100                          | 802 (77.0)                    | 588 (85.6)                                              |         |
| Unknown                         | 3 (0.3)                       | 5 (0.7)                                                 |         |
| Cognitive functioning           |                                |                                                        | 0.009‡ |
| 0–40                            | 44 (4.2)                      | 22 (3.2)                                                |         |
| 41–60                           | 67 (6.4)                      | 28 (4.1)                                                |         |
| 61–80                           | 200 (19.2)                    | 117 (17.0)                                              |         |
| 81–100                          | 727 (69.8)                    | 515 (75.0)                                              |         |
| Unknown                         | 3 (0.3)                       | 5 (0.7)                                                 |         |
such as chronic mental health, family problems and general stress rather than breast cancer, adding informative value to an earlier assessment of psychological problems in the START trials [27]. Adverse effects of local and systemic breast cancer treatment effects were expressed by women in their comments in addition to completing quality of life questions in these key areas, adding personal details of the impact of these treatment effects, such as on body image and sexuality. Comments about chronic or disabling conditions and comorbidities were expectedly frequent in an ageing population and reflect evidence of both incident and chronic disease in survivors [13]. These conditions are of concern as they can lead to an inferior prognosis and worse disease outcomes [13,19,28], as well as indicating supportive care needs.

Comments about fear of recurrence and existential concerns were the most prevalent in the new themes at 5 years and have been highlighted as a key problem in recent research [29,30]; other new issues reported may reflect women’s increased awareness of genetic aspects, second cancers and the effects of ageing during survivorship. Expressions of positive outcomes and praise for health care and trial participation showed good supportive care in the trials setting and far outweighed criticisms.

What is the Value of Self-reported Comments?

Women’s comments reveal the experience of cancer and the impact of adverse events and day to day difficulties, as well as the interrelatedness of health and personal or social circumstances. For example, losing a job after diagnosis can lead to developing depression. However, distinctions between the contribution of treatment and other causes (comorbidity, physiological) to reported symptoms can still be difficult to determine. The value of this additional information extends beyond the randomised comparisons. However, can patients’ free-text comments continue to make a valid contribution? Their utility has been endorsed in a large exploratory study of patients’ views of cancer care [34] in which the potential value of free-text comments was described as ‘illuminating’ when highlighting potential causes for some inferior outcomes in a survey of mixed cancer patients [35]. Novel ways of analysis of these data have also been described [36]. However, free-text comments usually require a time-consuming methodology and analysis that is likely to preclude frequent use in large studies. Currently free-text comments are being invited in

| Table 1 (continued) | Women who commented at 5 years $n = 1041$ (%) | Women who returned 5 year form but who did not comment $n = 687$ (%) | $P$-value |
|---------------------|---------------------------------------------|-------------------------------------------------|-----------|
| Fatigue symptoms    |                                             |                                                 | 0.001     |
| 0–40                | 793 (76.2)                                  | 578 (84.1)                                      |           |
| 41–60               | 167 (16.0)                                  | 67 (9.8)                                        |           |
| 61–80               | 59 (5.7)                                    | 30 (4.4)                                        |           |
| 81–100              | 21 (2.0)                                    | 10 (1.5)                                        |           |
| Unknown             | 1 (0.1)                                     | 2 (0.3)                                         |           |
| Pain symptoms       |                                             |                                                 | <0.001    |
| 0–40                | 859 (82.5)                                  | 618 (90.0)                                      |           |
| 41–60               | 71 (6.8)                                    | 34 (4.9)                                        |           |
| 61–80               | 70 (6.7)                                    | 17 (2.5)                                        |           |
| 81–100              | 40 (3.8)                                    | 15 (2.2)                                        |           |
| Unknown             | 1 (0.1)                                     | 3 (0.4)                                         |           |

Unknown categories excluded from significance tests.

* $t$-test.
† $\chi^2$ test for trend.
‡ $\chi^2$ test.
§ Education data collected at 1 year after randomisation, so not available for all participants.
‖ EORTC QLQ-C30 scores range from 0 to 100: higher scores indicate better functioning but worse symptoms.
two further radiotherapy trials run by the ICR in order to explore earlier stages of treatment and follow-up for which adequate data were not available in the START trials.

In support of our findings, we found no significant difference between the different treatment schedules of the START trials in terms of frequencies of comments and can therefore be confident that there was no specific bias to the quality of life results on that basis. The quality of life sample gave good representation with respect to age and geographic area for breast cancer populations [37]. Using a constant comparative methodology enabled us to describe comments on the diverse social and medical context of women’s breast cancer experience by creating distinct themes, but not to speculate on whether these women would be similar to age-matched population samples. We do not know if women

| Negative comments                                                                 | Number (% of 496) of women reporting theme at 5 years |
|----------------------------------------------------------------------------------|--------------------------------------------------------|
| **Chronic medical problems including physical functioning:**                      | 170 (34.3)                                              |
| Asthma, breathlessness, diabetes, heart disease, hypertension, chronic conditions, e.g. multiple sclerosis, migraine, Parkinson's disease, rheumatoid and osteoarthritis, fractures or falls, back or joint pain, fibromyalgia, muscle pain or injury, mobility problems | 170 (34.3)                                              |
| **Breast and related problems:**                                                 | 129 (26.0)                                              |
| Breast pain, arm lymphoedema, cancer recurrence in the breast, breast abnormalities, radiotherapy effects to the breast, body image | 129 (26.0)                                              |
| **Systemic treatment side-effects:**                                             | 108 (21.8)                                              |
| Tamoxifen side-effects, hot sweats, weight gain, sexual problems                 | 108 (21.8)                                              |
| **Surgery (excluding breast cancer-related surgery) and hospital admissions**    | 28 (5.6)                                                |
| Gynaecological, dental, or other surgery, orthopaedic, falls                      | 28 (5.6)                                                |
| **Acute or transient health problems:**                                          | 47 (9.5)                                                |
| Colds, viral infections, ‘stomach upset’                                         | 47 (9.5)                                                |
| **Psychological problems:**                                                      | 89 (17.9)                                               |
| Depression or taking antidepressant medication, history of mental illness (e.g. schizophrenia), anxiety disorders, panic attacks, stress | 89 (17.9)                                               |
| **Life events or family problems:**                                              | 43 (8.7)                                                |
| Bereavement, husband’s illness, house move, relationship problem                 | 43 (8.7)                                                |
| **Job problems:**                                                                | 10 (2.0)                                                |
| Redundancy, early retirement, job loss and other job-related issues              | 10 (2.0)                                                |
| **Other cancers:**                                                               | 12 (2.4)                                                |
| Any cancer other than second primary breast cancer/recurrence/metastasis          | 12 (2.4)                                                |
| **Aspects of care:**                                                             | 17 (3.4)                                                |
| Problems with diagnosis, treatment or follow-up, general practitioner or specialist | 17 (3.4)                                                |
| **Family history of cancer:**                                                    | 14 (2.8)                                                |
| Family members with cancer, genetic risk                                         | 14 (2.8)                                                |
| **Effects of aging:**                                                            | 40 (8.1)                                                |
| Older age affecting recovery, uncertain symptom attribution, e.g. tiredness       | 40 (8.1)                                                |
| **Future concerns:**                                                             | 55 (11.1)                                               |
| Cancer-related worries, fear of cancer recurrence                                | 55 (11.1)                                               |
| **Positive comments**                                                            |                                                         |
| **Good aspects of care:**                                                        | 149 (30.0)                                              |
| Gratitude to hospital staff and trials unit, felt well supported                 | 149 (30.0)                                              |
| **Good recovery from cancer:**                                                   | 80 (16.1)                                               |
| Feeling back to normal, positive attitude                                         | 80 (16.1)                                               |
| **Personal support:**                                                            | 27 (5.4)                                                |
| Support from friends, family, general practitioner, religion                     | 27 (5.4)                                                |
| **Positive life events:**                                                        | 16 (3.2)                                                |
| e.g. grandchildren, family births, marriage                                     | 16 (3.2)                                                |

Percentages add up to >100% as some women have commented in more than one category.

![Fig 1. Number of themes identified per person from the random sample of 500 women commenting at 5 years.](image-url)
commenting also reported and discussed their concerns with health professionals or received helpful interventions. Considering potential confounders in our study, we recognise that women who chose not to comment may have felt non-cancer problems were irrelevant or inappropriate. Their apparent enhanced quality of life may reflect more adaptive coping, favourable resilience or adjustment to adversity. Beneficial effects of existing social care, psychological or medical intervention may also play a part. Women commenting were better educated and slightly older, which may have enhanced response rates, while those receiving chemotherapy perhaps felt more impetus to report related problems.

In conclusion, this novel opportunity to synthesise quantitative and qualitative data in the START trials provides a broader understanding of the cancer experience and the influence of acute and chronic contextual problems. Awareness of our findings should help clinical teams to address the wider effects of contextual difficulties, comorbidity and late effects of treatment, and stimulate thought about the interpretation and future development of PROMs. Many women accept trial participation for altruistic reasons [38] and their feedback should help inform the provision of individualised supportive care for future patients.

Acknowledgements

We extend grateful thanks to the clinical teams, research nurses and trial co-ordinators involved in the START trials who recruited patients and assisted with data collection. Patients in the trials have provided high quality and quantity of data and we would like to thank all the participants. We acknowledge earlier statistical support from Georges Sumo and input to the qualitative analysis by Emma Jones and Natalie Atkins. We appreciate support and comments from the Trial Management Group: Rajiv Agrawal, Edwin Aird, Jane Barrett, Peter Barrett-Lee, Jacqueline Brown, Jane Dobbs, John Dewar, Peter Hoskin, Pat Lawton, Brian Magee, David Morgan, Roger Owen, Sandra Simmons, Mark Sydenham, Karen Venables, John Yarnold. The START trials were funded by Cancer Research UK (CRUK/96/001). The UK Medical Research Council and the UK Department of Health (grant...
G9600656). Continued data collection and analysis is made possible by a core grant from Cancer Research UK to the ICR-CTSU. We acknowledge NHS funding to the NIHR Biomedical Research Centre at the Royal Marsden and the ICR.

Appendix A. Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.clon.2018.03.007.

References

[1] Hopwood P, Haviland J, Sumo G, Mills J, Bliss JM, Yarnold J, on behalf of the START Trial Management Group. Randomised comparisons over 5 years of patient assessed breast, arm and shoulder symptoms and body image according to radiotherapy schedule for early breast cancer in the Standardisation of Breast Radiotherapy (START) trials. Lancet Oncol 2010;11(3):231–240.

[2] Start Trialists Group. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 2008;9(4):331–341.

[3] Start Trialists Group. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008;371(9618):1098–1107.

[4] National Institute for Health and Care Excellence (NICE). Early and locally advanced breast cancer: diagnosis and treatment. Clin Guidel 2009 (updated 2015). Available at: nice.org.uk/guidance/cg80.

[5] Constantini M, Mencaglia E, Guilio PD, Cortesi E, Roila F, Ballatori E, et al. Cancer patients as ‘experts’ in defining quality of life domains. A multicentre survey by the Italian Group for the Evaluation of Outcomes in Oncology (IGEO). Qual Life Res 2000;9(1):151–159.

[6] Costain Shou K, Hewison J. Experiencing cancer: quality of life in treatment, 1st ed. Buckingham: Open University Press; 1999.

[7] Brennan J. Cancer in context: a practical guide to supportive care. Oxford: Oxford University Press; 2004.

[8] Michael YL, Berkman LF, Colditz GA, Holmes MD, Kawachi I. Social networks and health-related quality of life in breast cancer survivors. A prospective study. J Psychosom Res 2002; 52(5):285–293.

[9] Ell K, Xie B, Wells A, Nedjat-Haiem F, Lee PJ, Vourlekis B. Economic stress among low-income women with cancer: effects on quality of life. Cancer 2008;112(3):616–625.

[10] Suppli NP, Johansen C, Christensen J, Kessing LV, Kromann N, Dalton SO. Increased risk for depression after breast cancer: a nationwide population-based cohort study of associated factors in Denmark, 1998–2011. J Clin Oncol 2014;32(34):3831–3839.

[11] Syrowatka A, Motulsky A, Kuteva S, Hanley JA, Dixon WG, Megruditchian AN, et al. Predictors of distress in female breast cancer survivors: a systematic review. Breast Cancer Res Treat 2017;165(2):229–245.

[12] Becker H, Kang SJ, Stuifbergen A. Predictors of quality of life for long-term breast cancer survivors with pre-existing disabling conditions. Oncol Nurs Forum 2012;39(2):122–131.

[13] Yancik R, Ganz PA, Varricchio G, Canley B. Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. J Clin Oncol 2001;19:1147–1151.

[14] Mols F, Vingerhoets Ad JJJM, Coebergh JW, van de Poll-Franse LV. Quality of life among long-term breast cancer survivors: a systematic review. Eur J Cancer 2005;41:2613–2619.

[15] Catt S, Starkings R, Shilling V, Fallowfield L. Patient-reported outcome measures of the impact on cancer patients’ everyday lives: a systematic review. J Cancer Surviv 2017;11(2):211–232. https://doi.org/10.1007/s11764-016-0580-1.

[16] Low CA, Stanton AL, Thompson N, Kwan L, Ganz PA. Contextual life stress and coping strategies as predictors of adjustment to breast cancer survivorship. Ann Behav Med 2006;32(3):235–244.

[17] Fenlon D, Kambhaita P, Hunter MS. Helping patients to help themselves after breast cancer treatment. Clin Oncol 2015;27:640–646.

[18] Fenlon D, Frankland J, Foster CL, Brooks C, Coleman P, Payne S, et al. Living into old age with the consequences of breast cancer. Eur J Oncol Nurs 2013;17(3):311–316.

[19] Louwman WJ, Janssen-Heijnen MLG, Houterman S, van der Slangen MJ, Nieuwenhuijzen GAP, et al. Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer 2005;41:779–785.

[20] Aaronson NK, Ahmedzai S, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer Q-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85(5):365–376.

[21] Sprangers MA, Groenewold M, Arraras JJ, Franklin J, te Velde A, Muller M, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 1996;14(10):2756–2768.

[22] Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361–370.

[23] Hopwood P, Fletcher I, Lee A, Al Ghazal S. A body image scale for use with cancer patients. Eur J Cancer 2001;37(2):189–197.

[24] Brown J, Mills J, Haviland J, Bliss J, Yarnold J. on behalf of the START Trial Management Group. Productivity and health effects of radiotherapy in breast cancer patients. Eur J Cancer 2003;1(3 suppl. 3):510.

[25] Pope C, Ziebland S, Mays N. Qualitative research in health-care: analysing qualitative data. Br Med J 2000;320. 7227.114.

[26] Fayers P, Aaronson NK, Bjordal K, Curran D, Groenvold M, et al. The European Organization for Research and Treatment of Cancer Q-C30 scoring manual, 3rd ed. Brussels: EORTC Quality of Life Group; 2001.

[27] Hopwood P, Sumo G, Mills J, Haviland J, Bliss JM. The course of anxiety and depression over 5 years follow-up and risk factors in women with early breast cancer: results from the UK Standardisation of Radiotherapy Trials (START). Breast 2010;19(2):84–91. https://doi.org/10.1016/j.breast.2009.11.007.

[28] Land LH, Dalton SO, Jensen MB, Ewertz M. Impact of co-morbidity on mortality: a cohort study of 62,591 Danish women diagnosed with early breast cancer, 1990–2008. Breast Cancer Res Treat 2012;131(3):1013–1020.

[29] Ellegaard MB, Grau C, Zachariae R, Bonde Jensen A. Fear of cancer recurrence and unmet needs among breast cancer survivors in the first five years. A cross-sectional study. Acta Oncol 2017;56(2):314–320.

[30] Flicker C, Dolbeault S, Sultan S, Bredart A. Prevalence, intensity and predictors of the supportive care of women diagnosed with breast cancer: a systematic review. Psycho-oncology 2013;23:361–374.
[31] Kotronoulas G, Kearney N, Maguire R, Harrow A. What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. *J Clin Oncol* 2014;32(14):1480–1501. https://doi.org/10.1200/JCO.2013.53.5948.

[32] Faithful S, Lemanska A, Chen T. Patient-reported outcome measures in radiotherapy: clinical advances and research opportunities in measurement for survivorship. *Clin Oncol* 2015;27:679–685.

[33] Hall E, Cameron D, Waters R, Barrett-Lee P, Ellis P, Russell S, *et al* TACT Trial Investigators. Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/001). *Eur J Cancer* 2014;50(14):2375–2389.

[34] Corner J, Wagland R, Glaser A, Richards M. Qualitative analysis of patients’ feedback from a PROMS survey of cancer patients in England. *BMJ Open* 2013;3(4). https://doi.org/10.1136/bmjopen-2012-002316. eoo2316.

[35] Bracher M, Corner J, Wagland R. Exploring experiences of cancer care in Wales: a thematic analysis of free-text responses to the 2013 Wales Cancer Patient Experience Survey (WCPES). *BMJ Open* 2016;6(9). https://doi.org/10.1136/bmjopen-2016-011830. e011830.

[36] Bracher M, Wagland R, Corner J. Learning-based text mining in analysis of free-text responses to the 2013 Wales Cancer Patient Experience Survey (WCPES) — Findings and future applications 09/10/2014. Available at: https://eprints.soton.ac.uk/372730/1/WCPES%2520TM%2520report.pdf.

[37] ONS General Household Survey Report 2004: Appendix G: Table 3.12 (Distribution of population by sex and age). Available at: webarchive.nationalarchives.gov.uk.

[38] Jenkins VA, Fallowfield LJ. For the benefit of others: reasons why women with breast cancer participate in RCT’s. *Breast Care* 2015;10:88–93. https://doi.org/10.1159/000376563.